BIIB Stock Analysis — Biogen
Sector: Healthcare
AI Verdict
Biogen trades at a steep discount to healthcare peers for explosive expected growth, and if its clinical pipeline holds up, this is cheap for the risk.
Competitive Moat
Biogen specializes in neurology-focused pharmaceuticals, with a defensible position in multiple sclerosis and Alzheimer's treatments due to deep clinical expertise and a pipeline of proprietary biologics. Its moat relies on high regulatory barriers and long development cycles that limit fast-following competition.
Summary
Biogen's stock is in focus as analysts expect a massive 66.5% jump in earnings over the next year.
Where It Stands
Biogen is up 53.63% over the past year, trades at 12.4x next year's earnings versus a healthcare sector median of 22x, and its RSI of 59.5 is neutral.
Key Metrics
- RSI: 59.5 — Neutral
- Trailing P/E: 20.7x
- Forward P/E: 12.4x
- PEG Ratio: 0.32
- Earnings Growth: +0.7%
- Revenue Growth: +0.0%
- Market Cap: $28.5B
- 1-Year Return: 53.63%
- 52-Week High: $205.97
- 52-Week Low: $119.18
Analyst Consensus
24 Buy · 18 Hold · 1 Sell (43 analysts)
Bull Case
You're paying just 12.4x forward earnings for 66.5% expected EPS growth, which is cheap for the growth on offer if Biogen's neurology pipeline delivers.
Bear Case
If the forward P/E reverts to the sector median of 22x, the current discount could disappear fast if earnings disappoint or the RSI drifts above 65.
Catalyst to Watch
Watch for clinical trial results or FDA decisions on new neurology drugs — positive data could justify the growth baked into the 12.4x forward multiple.